A randomized, controlled trial (RCT) shows that even at a higher dose and longer treatment duration, the antimalarial drug ivermectin didn't shorten the time to a sustained recovery from COVID-19.
What happened to the variants that once wreaked havoc? “For all intents and purposes, we can consider them gone,” said David Dowdy, an epidemiology professor at Johns Hopkins Bloomberg School of Public Health.
Recent Comments